ExploreWatchlistsPricing
  1. US-listed companies
  2. FATE THERAPEUTICS INC
  3. Financials
  4. EBITDA

FATE THERAPEUTICS INC (FATE)

Market cap
$135.27M
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2024-191+11.07%
Dec 31, 2023-172-41.54%
Dec 31, 2022-295+39.55%
Dec 31, 2021-211+68.90%
Dec 31, 2020-125+26.84%
Dec 31, 2019-99+49.55%
Dec 31, 2018-66+60.10%
Dec 31, 2017-41+32.40%
Dec 31, 2016-31+14.71%
Dec 31, 2015-27+11.01%
Dec 31, 2014-24+60.93%
Dec 31, 2013-15

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat